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Abstract 
Background: Epidemiological surveillance is a key activity in malaria control and elimination in low‑transmission and 
pre‑elimination settings. Hence, sensitive tools for estimating malaria force of infection are crucial. Serological mark‑
ers might provide additional information in estimating force of infection in low‑endemic areas along with classical 
parasite detection methods. Serological markers can be used to estimate recent, past or present malaria exposure, 
depending on the used markers and their half‑life.
Methods: An assay based on 14 Plasmodium‑specific peptides, one peptide specific for Anopheles gambiae saliva 
protein and five Plasmodium‑specific recombinant proteins was developed for the MAGPIX system, assessed for its 
performance, and applied on blood spots from 2000 individuals collected in the Ratanakiri Province, Cambodia.
Results: A significant correlation for the use of 1000 and 2000 beads/antigen/well as well as for the monoplex versus 
multiplex assay was observed for all antigens (p < 0.05). For the majority of antigens, antigen‑coupled beads were 
stable for at least 2 months. The assay was very reproducible with limited intercoupling, interplate and intraplate vari‑
ability (mean RSD <15 %). Estimating seroconversion and seroreversion per antigen using reversible catalytic models 
and models allowing two seroconversion rates showed higher seroconversion rates in adults.
Conclusion: The multiplex bead‑based immunoassay was successfully implemented and analysis of field blood 
samples shows that changes detected in force of malaria infection vary according to the serological markers used. 
Multivariate analysis of the antibody responses and insights into the half‑life of antibodies are crucial for improving 
the interpretation of these results and for identifying the most useful serological markers of past and recent malaria 
infection.
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Background
Globally an estimated 3.4 billion people in 107 malaria-
endemic countries are at risk of malaria, of which 1.2 
billion at high risk [1] live mostly in the African region 
(47  %) and the Southeast Asian region (37  %). To con-
trol and eliminate malaria, WHO recommends a 
multi-pronged strategy, which includes vector control 
interventions, preventive therapy, diagnostic testing, 
treatment with quality-assured artemisinin-based combi-
nation therapy (ACT) as well as strong epidemiological 
surveillance [1]. Through upscaling of several elements of 
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this strategy, many countries are on the verge of reach-
ing pre-elimination. The low transmission rates in these 
areas pose considerable challenges for epidemiological 
surveillance [2], hindering the evaluation of new (vector) 
control tools necessary to reach elimination [1].
Detection of malaria-infected persons by microscopy, 
rapid diagnostic tests (RDTs) and even PCR lacks sen-
sitivity because of low numbers of positive samples [3], 
representing a formidable logistical challenge due to the 
very big sample sizes required in surveillance and evalu-
ation surveys. While parasite-prevalence (measured by 
microscopy, RDTs or PCR) provides a snapshot of the 
exposure to malaria, the use of serological markers can 
provide a picture of the malaria transmission over a pro-
longed period [3, 4]. Serology is based on the detection of 
antibodies (Abs) against antigens (Ags) of malaria para-
sites, which offers an advantage as anti-Plasmodium Abs 
can persist for months after infection. Therefore, these 
Abs have been suggested as indicators of malaria trans-
mission [5–8], and are believed to be a better approach to 
determine past, recent and present malaria exposure [9]. 
Previous studies performed in low transmission settings, 
such as Cambodia, also suggest that serological assays are 
promising for indicating malaria transmission [3, 10–12].
Since the 1960s, serological markers detected by indi-
rect immunofluorescence antibody tests (IFAT) were 
used to assess malaria transmission intensity and reduc-
tions in transmission [13]. This has proven to be a reliable 
and useful serological test for malaria in epidemiological 
surveys [5, 6, 14]. However, variation in source of Ags and 
the subjectivity of IFAT has led to this method falling out 
of favour [4]. Standardized tests based on recombinant 
Ags used in an enzyme-linked immunosorbent assay 
(ELISA) were therefore developed [4, 7–9]. However, an 
ELISA can only assess one marker at a time, making it 
labour intensive and time consuming when interested in 
multiple Ab responses. In the context of malaria elimina-
tion it will become essential to take into account individ-
ual variations in Ab responses, the occurrence of multiple 
malaria parasites [15], as well as to increase the probabil-
ity of measuring changes in Ab responses by combin-
ing different markers. Recently, several multiplex assays 
that were testing for different serological markers in the 
same blood sample, were developed by different research 
teams based on the Luminex technology [15–18].
In this context, the general objective of this study was 
to implement an existing assay based on the Luminex 
technology for detection of Abs against malaria para-
sites in blood samples from Ratanakiri Province, Cambo-
dia. This is the first and most extensive multiplex assay 
in malaria serology executed in the Southeast Asian 
region, including 20 Ags (recombinant proteins and pep-
tides) directed against different specific malaria parasites. 
Furthermore, this study includes a detailed analysis on 
the stability of coated beads over time and the reproduc-
ibility of the beads coupling and immunoassay.
Methods
Samples
A positive control for the assay was prepared by pooling 
sera from four Plasmodium falciparum- and two Plasmo-
dium vivax-infected patients from Ratanakiri Province in 
Cambodia. Dilutions of this positive control pool were 
prepared at 1:100, 1:400 and 1:1600 in PBS-CR (phos-
phate buffered saline, Charles River Laboratories Inc, 
MA, USA). These dilutions were used to assess the per-
formance of the assay and as positive control samples in 
the immunoassay applied on field blood samples. The lat-
ter were collected in Ratanakiri Province, Cambodia, on 
filter papers through finger prick, during April–May 2012 
(baseline survey of the MalaResT project, NCT01663831, 
that aims to evaluate the use of topical repellents, in addi-
tion to long-lasting insecticidal nets, on malaria preva-
lence and incidence [19, 20]). Out of 5392 blood spot 
samples collected, 2000 were randomly chosen for the 
immunoassay and after quality control, 1931 samples 
were used for data analysis. Blood spot filter papers were 
prepared by punching two discs of 4-mm diameter, and 
eluted overnight in 160  μL of PBS-TBN (dilution 1:40, 
PBS-1 % BSA-0.15 % Tween, pH 7.4, Sigma-Aldrich). Just 
before use in the immunoassay, the eluted samples were 
further diluted to 1:200 in PBS-CR.
Antigens
Selection of peptides specific for P. falciparum repre-
senting different life stages of the parasite was based on 
the work of Ambrosino et  al. [5]. Additionally, peptides 
specific for Anopheles gambiae saliva protein [5], P. vivax 
and Plasmodium malariae were included in the assay, as 
well as specific recombinant proteins for P. falciparum 
and P. vivax (Table 1). All peptides were chemically syn-
thesized with an added N-terminal cysteine residue and 
bovine serum albumin (BSA) (Table 1) [5] by GeneCust 
Europe (Dudelange, Luxembourg). The recombinant pro-
teins were synthesized as described in Table 1. This study 
consisted of two phases (performance assessment of the 
assay, and application to field samples; Fig. 1). For prac-
tical reasons, some steps carried out during the perfor-
mance assessment used a slightly different Ag set (Fig. 1).
Covalent coupling of antigens to the beads/microspheres
Covalent coupling of paramagnetic beads (MagPlex 
microspheres, Luminex Corp, Austin, TX, USA) was 
carried out as described by Ambrosino et al. [5] and the 
Luminex Corp [21, 22]. Each Ag was coupled at a con-
centration of 4 μg Ag/106 beads to 1 × 106 beads/beadset 
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for performance assessment (Fig. 1). When applying the 
assay on blood samples from Ratanakiri, all Ags were 
coupled twice to 5 ×  106 beads/beadset, and mixed for 
homogenous coupling. BSA (Sigma-Aldrich, St Louis, 
USA) was coupled to an additional set of beads to serve 
as a background control [5, 23].
Bead‑based immunoassay
The immunoassay was carried out as described pre-
viously [5, 17, 22, 24, 25], with minor adjustments. A 
microsphere working mixture was prepared in PBS-
CR, with a concentration of 1000 beads/Ag/well (except 
in the experiment to assess the difference between a 
Table 1 Overview of the antigens (peptides and recombinant proteins) used in this study
Ags are organized according to the Plasmodium species and the life-cycle stages in the human host
Antigens Sequence (N‑terminal 
to C‑terminal)





2557.67 Sporozoite P. falciparum Peptide [5]
Pfl3 C‑terminal His‑tag produced 
in E. coli
Sporozoite P. falciparum Recombinant protein [45, 46]
STARP‑R STDNNNTKTISTDNNNTKTIC 2299.42 Sporozoite and liver stage P. falciparum Peptide [5, 47]
SALSA 1 SAEKKDEKEASEQGEESHKKEN‑
SQESAC
3123.24 Sporozoite and liver stage P. falciparum Peptide [5, 47]
SALSA 2 NGKDDVKEEKKTNEKKDDGKT‑
DKVQEKVLEKSPKC
4019.52 Sporozoite and liver stage P. falciparum Peptide [5, 47




5297.97 Liver stage P. falciparum Peptide [5, 6, 48]
LSA1‑J ERRAKEKLQEQQSDLEQRKADT‑
KKC
3046.43 Liver stage P. falciparum Peptide [5, 47, 48]
LSA3‑NR2 VLEESQVNDDIFNSLVKS‑
VQQEQQHNVC
3230.53 Liver stage P.falciparum Peptide [5, 47]
LSA3‑RE VESVAPSVEESVAPSVEESVAEN‑
VEESVC
2991.2 Liver stage P. falciparum Peptide [5, 47]
PfMSPl‑19 Glutathione S‑transferase 
(GST) fusion protein. C‑ter‑
minal expressed in E. coli
Merozoite P. falciparum Recombinant protein [4, 24]
GLURP EDKNEKGQHEIVEVEEILC 2241.47 Trophozoite P. falciparum Peptide [5, 47, 49]
GLURP‑P3 EPLEPFPTQIHKDYKC 1945.23 Trophozoite P. falciparum Peptide [5, 47, 50]
PfGLURP‑R2 C‑terminal produced in E. coli Trophozoite P. falciparum Recombinant protein [49]
Pvlike CSP APGANQEGGAAAPGANQEG‑
GAAAPGANQEGGAAC
2892.99 Sporozoite P. vivax Peptide [47]
PvVK210 CSP DGQPAGDRAAGQPAG‑
DRADGQPAGDRADGQPAGC
3206.3 Sporozoite P. vivax Peptide [47, 51, 52]
PvVK247 CSP ANGAGNQPGANGAGNQP‑
GANGAGNQPGANGAGNC
2905.95 Sporozoite P. vivax Peptide [47, 51, 52]
PvCSP‑chimera Soluble His‑tag protein 
expressed in wheat‑germ 
cell free expression system
Sporozoite P. vivax Recombinant protein [51, 52]
PvAMAl Merozoite P. vivax Recombinant protein [53, 54]
PvDBP Merozoite P. vivax Recombinant protein [55]
PvMSPl‑19 C‑terminal produced in the 
baculovirus expression 
system
Merozoite P. vivax Recombinant protein [4, 16, 24]
PmCSP GNAAGNAAGNDAGNAA‑
GNAAGNAAGNAAGNAAC
2358.37 Sporozoite P. malariae Peptide [47]
SALIV 1 EKVWVDRDNVYCGHLDC‑
TRVATFC
2830.22 Salivary gland proteins An. gambiae Peptide [5, 56]
SALIV 2 ATFKGERFCTLCDTRHFCECK‑
ETREPLC
3324.84 Salivary gland proteins An. gambiae Peptide [5, 56]
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concentration of 2000 and 1000 beads/Ag/well). For the 
monoplex assay the microsphere working mixture con-
sisted of only one beadset with a coupled Ag, whereas 
it consisted of a pool of all coupled beadsets for the 
multiplex assay. In a 96-well plate  25  μl of the micro-
sphere working mixture (at 40 beads/μl) was added per 
well and 50  μl of serum sample (1:200 dilution) [24]. 
Plates were incubated at room temperature in the dark 
for 1 h on a plate shaker (600 rpm). Plates were washed 
three times, and 100  μl/well of secondary antibody 
(R-phycoerythrin+-conjugated AffiniPure F(ab′)2 frag-
ment of goat anti-human IgG, Jackson Immuno Research 
Laboratories) at a dilution of 1:500 was added [24]. Plates 
were incubated for 30 min in the dark at room tempera-
ture, and washed three times. Beads were resuspended in 
100 μl of 5 % PBS-BSA, pH 7.4, and read by the MAG-
PIX® system. A minimum of 400 beads per spectral 
address were analysed and results were expressed as the 
median fluorescence intensity (MFI) [5, 25, 26].
Experiments to assess the performance of the multiplex 
immunoassay
For performance assessment, two bead concentrations of 
1000 and 2000 beads/Ag/well were compared. The assays 
performed in monoplex (each Ag separately) and multi-
plex (all Ags pooled) were compared. Both assays were 
carried out in triplicate on the positive control pool dilu-
tions (1:100, 1:400, 1:1600) as previously described [5, 
25].
Stability of the Ag coupled beads was assessed by per-
forming a multiplex assay directly after coupling the 
beads and after storage at 4  °C during two, three, four, 
eight, and 16 weeks.
Reproducibility of the beads coupling was tested by 
coupling all Ags at three different time points, followed 
by an immunoassay on positive control pool dilutions 
(inter-coupling variability) [17]. Inter- and intraplate 
reproducibility of the immunoassay was assessed by per-
forming the assay on the positive control pool dilutions 
Fig. 1 Overview of the study, indicating the antigens used in each step
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on three different plates at different time points in 1 day. 
This was carried out on three different days (interplate 
variability) and in each plate the positive control pool 
dilutions were analysed in six-fold (intraplate variability) 
[27]. In addition, the inter- and intraplate variability was 
assessed by looking at the positive control pool samples 
added to each plate with the field blood samples.
Analysis of field samples
The immunoassay was applied on 2000 field blood sam-
ples. Therefore, the microsphere working mixture was 
prepared at a final concentration of 1000 beads/Ag/
well. All field blood spots were analysed in duplicate on 
separate plates. In each plate, the positive control pool 
dilutions (1:100, 1:400, 1:1600), negative control serum 
(1:200) and blanco (PBS-CR) were analysed in duplicate. 
In total, 50 plates were analysed and read by the MAG-
PIX® system.
Data analysis
All data were incorporated and analysed with R soft-
ware package version 3.1.0. [28]. Results were corrected 
for background signal by subtracting the signal obtained 
with BSA-coupled beads (MFIBSA) to the median 
value of the Ag-coupled beads (MFIAg), defined by: 
ΔMFI = MFIAg − MFIBSA [25].
Data analysis for performance assessment
Ags of which the positive control sera did not give a 
clear signal (ΔMFI < 1500) were excluded from the data-
analysis for performance assessment. Non-parametric 
Spearman’s rank correlation tests were used to analyse 
the relation between the ΔMFIs for comparing 2000 vs 
1000 beads/Ag/well, as well as the monoplex versus the 
multiplex assay. Correlations were considered significant 
at p <0.05. Segmented regression models were used for 
assessing the stability of the beads over time (R package 
‘segmented’ [28]). First the breakpoint per Ag and per 
dilution was estimated, followed by choosing the best 
linear model through ANOVA tests. Ags showing simi-
lar breakpoints in time were grouped and the segmented 
regression model was rerun on the grouped Ags, tak-
ing into account the Ags and dilutions as factor. Mean, 






] expressed as a percentage of the 
mean were calculated from the ΔMFI for assessing the 
reproducibility of the assay.
Quality control of the multiplex assay when applied 
on field blood samples
To assure the validity of the plates for screening the field 
blood samples, a quality control was performed on the 
ΔMFI values of the high positive control pool samples 
and on the percentage positivity (PP) calculated from 
the low positive control pool samples. Results were plot-
ted in Levey Jenning Charts (see Additional file  1) and 
plates with samples that fell out of −2SD and +2SD were 
rejected and repeated. After quality control, ΔMFI values 
of each sample and its duplicate were normalized for each 
Ag using the value of the high positive control (which was 
in the linear range of the assay). For this purpose, ΔMFI 
was converted to PP ( ∆MFIsamples(Ag1)
∆MFI High positive control(Ag1)
× 100% ) 
and then the mean PP of the two duplicate samples was 
calculated. For each sample, the result was rejected when 
the RSD (relative standard deviation) of two duplicate 
results exceeded 30 %. The results of a total of 1931 sam-
ples were accepted for further analysis.
Estimation of the force of infection per antigen
To estimate the seroprevalence per Ag, a cut-off value 
per Ag was generated by fitting a normal mixture model 
on the transformed data using the natural logarithm of 
(PP + 1) [4]. The mean of the negative distribution +3SD 
was defined as threshold for seropositivity [4]. These 
dichotomized serological results were used to fit a simple 
reversible catalytic conversion model based on maximum 
likelihood. This model estimates one seroconversion rate 
(SCR, λ) that represents the force of infection and one 
seroreversion rate (SRR, ρ) per Ag for all individuals [4, 7, 
9], expressed per person per year. Next, a model estimat-
ing two SCRs and one fixed SRR varying across different 
age groups was fitted. The breakpoint in age was selected 
using V-fold cross-validation (VFCV) [10]. VFCV ran-
domly partitioned the data into a validation- and train-
ing-set. The cross-validation process was repeated five 
(V) times on the training set and at least once on the vali-
dation set. All V results were averaged to one single value 
(breakpoint). Partitioning the data avoids overfitting [10, 
29]. Both models were compared through the likelihood 
ratio test (LRT) at p <0.05 [10, 30].
Ethical clearance
The study protocol was reviewed and approved by the 
Cambodian National Ethics Committee on Health 
Research (Approval 265 NECHR), the Institutional 
Review Board of the Institute of Tropical Medi-
cine Antwerp (Approval IRB/AB/ac/154) and the 
Ethics Committee of the University of Antwerp (Approval 
B300201112714). Gatekeepers provided informed writ-
ten consent for the participation of their village. The sur-
vey participant or his/her parents or guardian provided 
informed written consent for individual participation.
Results
No clear ΔMFI signal was found for the positive con-
trol sera for Ags SR11.1, PvlikeCSP, PvVK210CSP, 
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PvVK247CSP, PmCSP, SALIV1 and SALIV2 
(ΔMFI < 1,500). These antigens were therefore excluded 
from further analysis in the performance assessment 
(Fig. 1).
Performance assessment of the multiplex immunoassay 
using 1000 performs as good as 2000 beads/Ag/well
The ΔMFIs obtained from the assays using 1000 and 
2000 beads/Ag/well were significantly correlated (Spear-
man’s Rank correlation p < 0.05; R2 = 0.972; Fig. 2a). For 
most Ags, a slightly higher ΔMFI was observed when 
using 1000 beads/Ag/well as compared to 2000 beads/
Ag/well (Additional files 2, 3), and this for all dilutions of 
the positive control pool (1:100, 1:400 and 1:1600).
Multiplexing beads does not affect the assay results
Similar ΔMFI-signals were obtained in monoplex and 
multiplex (Additional files 2, 3), with a clear correlation 
for all Ags between the ΔMFIs obtained by the monoplex 
and the multiplex assays (R2 = 0.972; p < 0.05; Fig. 2b).
Stability of the coupled beads depends on the antigens 
used
Segmented regression models distinguished three groups 
of Ags, each with a similar ΔMFI trend over time (Fig. 3). 
For these three groups, different breakpoints (i.e., points 
in time at which the trend in ΔMFI changes) were 
observed at 3, 6 and 7 weeks after coupling. For the Ags 
with lower ΔMFI values (CSP, Pf13, STARP-R, SALSA2, 
PvCSP, PvAMA1, and PvDBP) an earlier break in trend 
is observed, but with a low ΔMFI decay over time after 
the breakpoint (Fig. 3; Additional file 4). In general, for all 
Ags except for PvCSP, the decay in ΔMFI after 8 weeks 
was less than 10 % (Additional file 4). As such, the cou-
pled beads can be used for at least 8 weeks after coupling.
The immunoassay is reproducible
Intercoupling, intraplate and interplate reproducibil-
ity was assessed per Ag by evaluating the RSD values 
(Fig.  4). The ΔMFI results were divided into three dif-
ferent groups (<5000; 5000; ≤15,000; >15,000). Highest 
RSD values were observed for the lowest ΔMFI values 
(<5000). In general, the upper limits of the interquar-
tile ranges were lower than 15 % [inter-coupling 11.9 % 
(8.5–15.2  %), interplate 7.9  % (6.1–12.4  %), intraplate 
5.7 % (3.0–12.7 %)] which indicates an acceptable repro-
ducibility [27]. The intraplate and interplate variability 
was also assessed by analysing the RSD on the ΔMFI of 
the high, medium and low positive control pool dilu-
tions used as a quality control on the 50 plates with field 
blood samples (Fig.  5). A low variability was observed 
for the intraplate reproducibility [RSD 2.7  % (IQR: 
1.2–5.1  %)]. The interplate variability was higher than 
experimentally determined during the performance 
assessment [RSD 18.6  % (IQR: 16.5–20.1  %)], but still 
acceptable.
Fig. 2 Correlation between the ΔMFI values obtained from analysing the positive control pool with the bead‑based assay a using 1000 and 2000 
beads/Ag/well, and b in the monoplex and multiplex format
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Application of the assay on blood samples collected 
in Ratanakiri
Quality control of the high positive control serum
A total of 2000 field blood samples were analysed in 
duplicate in a total of 50 96-well plates. These plates were 
validated based on the Levey Jenning Charts of the ΔMFI 
of the high positive controls and the PP of the low posi-
tive controls (Additional file 1). The stability of the ΔMFI 
signal of the positive control pool over the analysis of 
the plates was confirmed by segmented regression, as 
no breakpoint could be found for the Ags. Based on the 
duplicate results of the field blood samples, the results of 
1931 blood samples were validated for further analysis.
Estimating age‑group specific seroconversion rates 
per antigen
After dichotomizing the serological results for all blood 
samples based on a cut-off value, age-seroprevalence 
curves were constructed and reversible catalytic conver-
sion models allowing one and two SCRs were fitted to the 
data (Fig. 6; Additional file 5). The force of malaria infec-
tion between age groups was shown for 6 out of 20 Ags 
(CSP, SALSA2, LSA3-RE, PfGLURP-R2, PvVK210CSP, 
and PmCSP), with the time of change obtained through 
V-fold cross-validated plots (Additional file  6) ranging 
between 10 and 20  years. Higher SCRs were observed 
for the higher age groups for these Ags. When com-
paring the SCRs and SRRs between serological mark-
ers used (Fig. 7), large differences were observed among 
serological markers used for different life stages of the 
same parasite, as well as for different parasites. Within 
the population, highest annual SCRs were modelled for 
Ags LSA3-RE (0.085 per person per year) and PfMSP1-
19 (0.076 per person per year) and lowest annual SCRs 
for Ags SALSA1, SR11.1, PvlikeCSP, STARP-R, and 
PvVK210CSP (ranging from 0.007 to 0.009 per person 
Fig. 3 The stability of the coupled beads as determined by segmented regression analysis taking into account antigens and dilutions as factor. 
Beads were tested at different time points after coupling and the breakpoints in time were estimated by segmented regression analysis. The trend 
in ΔMFI shows different breakpoints for three groups of antigens, namely a 3 weeks after coupling (CSP, Pf13, STARP‑R, SALSA2, PvCSP, PvAMA1, and 
PvDBP), b 6 weeks after coupling (LSA1‑J, LSA3‑RE, GLURP) and c 7 weeks after coupling (LSA1‑41, PfMSP1‑19, PfGLURP‑R2, and PvMSP1‑19)
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per year). Highest annual SRRs were modelled for Ags 
LSA3-NR2 (0.128 per person per year) and SALIV 2 
(0.083 per person per year), and lowest for Ags LSA3-RE, 
PfGLURP-R2, GLURP, SR11.1, PvVK210CSP, and PmCSP 
(ranging from 0.002 to 0.005 per person per year). 
Discussion
This is the first implemented multiplex assay for malaria 
serology in Southeast Asia. Moreover, with the use of 
20 specific Ags against different Plasmodium parasites 
(Table 1), this assay is the most extensive multiplex assay 
published on malaria serology, besides Helb et  al. [32]. 
In contrast to most studies, the Abs that can be detected 
are not only directed against one or two different Plas-
modium parasites [5, 10, 17, 24, 25, 33], but responses 
against P. falciparum, P. vivax, P. malariae, and An. 
gambiae are simultaneously detected. This is important 
in malaria elimination programmes, and especially in 
Southeast Asia where all four human malaria parasites 
as well as Plasmodium knowlesi are co-occurring [34]. 
Unfortunately at this stage, Ags specific for Plasmo-
dium ovale and P. knowlesi were not available and thus 
not included in the assay. As the final aim of the study 
was to analyse 2000 field blood samples, the stability of 
the coated beads over time and the reproducibility of the 
assay were first thoroughly assessed and proved to be 
satisfactory.
Previously it has been shown that multiplex-based 
serological studies are useful for detecting anti-Plasmo-
dium Abs [5, 10, 15, 17, 18, 24, 25] as well as Abs against 
other pathogens [31, 35–38]. Also in the present study, 
the technique was shown to be reliable and fast in detect-
ing several serological markers at once. All samples were 
analysed in less than 8 weeks of time, and more recently, 
Fig. 4 Reproducibility of the bead coupling and immunoassay determined experimentally by analysing the positive control pool. The relative 
standard deviation (RSD, y‑axis) is plotted in relation to the mean ΔMFI values (x‑axis) obtained from the assay. The boxplots represent the 75th 
percentile, median and 25th percentile of the RSD values from the a intercoupling‑, b intraplate and c interplate variability per dilution (1:100, 1:400 
and 1:1600). Whiskers represent the maximal and minimal outlier limits
Fig. 5 Reproducibility of the immunoassay based on the quality control samples in the immunoassay applied on field collected samples. The rela‑
tive standard deviation (RSD, y‑axis) is plotted in relation to the mean ΔMFI values (x‑axis) obtained from the assay. The boxplots represent the 75th 
percentile, median and 25th percentile of the RSD values from the intercoupling, intraplate and interplate variability per dilution (1:100, 1:400 and 
1:1600). Whiskers represent the maximal and minimal outlier limits
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over 8000 samples were analysed in duplicate in the same 
timeframe, showing the possibility to upscale the sample 
throughput. However, complexity, high investment costs 
in purchasing a Luminex Analyzer and need for special 
training, prevent widespread use as compared to ELISA 
[5, 6]. A major restriction of this study is the use of the 
pool of control serum, as this has to be the same during 
the entire study, adequate quantities should therefore be 
Fig. 6 Age‑seroprevalence curves for all antigens analysed by the multiplex assay. Reversible catalytic conversion models allowing one (dashed 
black line, Model 1) and two (red solid line, Model 2) seroconversion rates were fitted to the data. For six Ags the model allowing two SCRs fitted bet‑
ter as compared to one SCR
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Fig. 7 Comparison of seroconversion and seroreversion rates between serological markers. The estimated SCRs of reversible catalytic conversion 
models allowing one (λ) and two (λ1 and λ2) SCRs are plotted with their 95 % confidence intervals. The SRRs are obtained from the model allowing 
one SCR. Antigens are sorted per parasite and life stage
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prepared and stored in advance. In previous studies, sat-
isfactory evidence has been presented on the validation 
of bead-based in comparison to ELISA [5, 39], and this 
was, therefore, not further explored in the present study.
Several features were considered to assess the perfor-
mance of the assay. In accordance to previous observa-
tions [17], this study confirmed that a reduction of the 
beads to 1000 beads/Ag/well leads to similar results as 
compared to the amount of beads recommended by the 
standard protocols for Luminex-based multiplex immu-
noassays (2000 or 5000 beads/Ag/well). A rough cost 
estimation indicates that the use of 1000 instead of 2000 
beads/Ag/well reduces the assay costs by one-third. 
Moreover, the results of previous studies [5, 15, 17] in 
which monoplex assays resulted in highly comparable 
ΔMFI values as multiplex assays were confirmed. This 
refutes the concern on cross-reactivity between the dif-
ferent Ag-coupled beads or blocking of Ab responses 
[15].
The obtained results of the performance assessment 
revealed that most of the coated beads were stable for 
up to 2 months, except for Ag PvCSP. This is important 
as screening approximately 2000 blood spot samples in 
duplicate took about 7 weeks from the first coupling until 
the last immunoassay (based on the results 1143 samples 
can be analysed per week). This stability is lower com-
pared to previous studies, stating that beads are stable for 
up to 3 or 7 months [5, 33], except for Ag STARP-R which 
was previously shown to be stable for only 1 month [5].
Good reproducibility is an important aspect of an assay 
as it guarantees that results obtained with the assay per-
formed on different plates and at different time points are 
comparable to each other. In the experimental set-up used 
in this study, there is no big difference in reproducibility 
between and within different plates as shown by similar 
RSDs. This is in line with other studies that showed accu-
rate and repeatable results according to the interplate, 
intraplate [5, 15, 27, 31], and intercoupling [40] reproduc-
ibility of multiplex assays. In this study, the reproducibility 
was also assessed by looking at the results obtained from 
the positive control pool dilutions analysed in duplicate 
on each of the plates used for screening 2000 blood sam-
ples from Ratanakiri Province (total of 50 plates). A much 
smaller intraplate variability (RSD <3  %) was observed 
compared to the experimental set-up, which was probably 
due to the fact that samples were only tested in duplicate 
instead of six times in the experimental set-up. A higher 
interplate variability was observed, which was still accept-
able (RSD <25 %) [27], and most probably due to the use 
of only two positive controls per plate.
In the present assay the use of peptides and recombi-
nant proteins was combined. Fourteen Plasmodium-
specific peptides (CSP, STARP-R, SALSA1, SALSA2, 
SR11.1, LSA1-41, LSA1-J, LSA3-NR2, LSA3-RE, GLURP, 
GLURP-P3, PvlikeCSP, PvVK210CSP, and PmCSP), 
one peptide specific for the An. gambiae saliva protein 
(SALIV2), and five Plasmodium-specific recombinant 
proteins (Pf13, PfMSP1-19, PfGLURP-R2, PvDBP, and 
PvMSP1-19) were included in the immunoassay.
After assessment of its performance, the multiplex 
assay was applied to blood spot samples collected in 
Ratanakiri Province in Cambodia to detect Ab responses 
against 20 different Ags. The seroconversion rate (SCR) 
was then estimated per Ag by constructing age-sero-
prevalence curves based on a threshold approach. This 
is currently the most frequently used way of analysing 
serological data in malaria epidemiology [4, 7], but which 
until the present was not applied to data from multiplex 
assays. By fitting models allowing two SCRs [10], age 
groups exhibiting similar SCRs can be defined. For six 
out of 20 Ags (CSP, SALSA2, LSA3-RE, PfGLURP-R2, 
PvVK210CSP, and PmCSP), the models allowing two 
SCRs fitted better, and a higher SCR was observed in the 
older age group. This observation corroborates results 
obtained in previous studies in Cambodia using GLURP 
and MSP1-19 as serological markers [9]. A lower SCR 
in the younger age groups may indicate a lower malaria 
exposure in the age group. This can be attributed to 
reductions in malaria transmission over time because 
of intensified malaria control interventions in the last 
years, or to different risk behaviour linked to the age 
groups [9]. Moreover, another explanation would be that 
children might lose their malaria-specific Abs faster [9]. 
Indeed, previous studies on malaria serology have shown 
that Ab responses in adults fluctuate to a lesser extent 
than in children [41, 42]. The statistical model fit used to 
obtain the estimates for the serological parameters was 
constrained to have two constant (i.e. age-independent) 
SCRs and one constant sero-reversion rate (SRR). More 
elaborate model fitting incorporating age-dependent 
SCRs and SRRs fell outside the scope of this study.
Until the present very limited information was avail-
able on the half-life of the Ab responses to the Ags used 
and on the individual variation in those responses. This 
is crucial for interpreting the results obtained with this 
assay. Serological markers with a long half-life can be used 
for assessing past exposure, while a short half-life will be 
useful for assessing recent or even present exposure. The 
present study has obtained information on the Ab half-
life estimated from the SRR as modelled in the reverse 
catalytic model [43]. Based on this information, fluctua-
tions in Ab half-life were observed per Ag, but all of them 
seem to have a relatively long half-life (ranging from 5 to 
>100 years). Most studies assume a fixed SRR independ-
ent of age and transmission rate [30]. A study based on 
one Ag (PfMSP1-19) [10] compared longitudinal and 
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cross-sectional data (children ages ≤11  years), showing 
a high concordance of SCRs between both study designs, 
while large discrepancies were seen between the SRRs. A 
follow-up study based on a selected combination of Ags 
(10 out of 655) that compared Ab-responses at individual 
and population level also shows reliable rates of expo-
sure [32]. The present study is based on cross-sectional 
sampling and the obtained SRRs are probably not reli-
able. More extensive analysis on the half-life of these Ab 
responses is planned by using sequentially collected blood 
samples from the same individuals, as well as by exploring 
which of the Ab responses can best capture the fluctua-
tions in malaria prevalence and incidence observed over 
time. SCR estimates based on a single serological marker 
can give a good indication of the force of infection [4, 
7]. However, combining the signal from multiple mark-
ers representing different life-stages of the parasite in an 
individual could help reducing individually heterogene-
ous responses to one particular marker, thereby provid-
ing more accurate estimation of the force of infection. A 
recent follow-up study conducted on a cohort of children 
demonstrated that measuring Ab-responses to a selection 
of few Ags provide an accurate estimate of exposure for 
individuals and communities [32]. Therefore, further data 
analysis performed with multivariate analysis should pro-
vide added value. Moreover, presently it is not possible to 
exploit the full potential of the assay to take into account 
individual variation in Ab responses, as analysis of the 
SCR is still carried out Ag by Ag. Data analysis methods 
to combine Ab responses for estimation of SCRs exist [44] 
and are currently being extended in the context of this 
multiplex assay for detection of anti-Plasmodium Abs.
Conclusion
As many countries engage in malaria elimination it is 
crucial to improve the understanding of the effective-
ness of additional malaria control tools and to be able to 
identify malaria hotspots for targeted and effective inter-
ventions in countries in an advanced elimination phase. 
With the current malariometric and entomological tools 
it is challenging to determine the malaria transmission 
rate in areas where prevalence of infection and incidence 
is decreasing. The multiplex assay measuring serological 
markers for malaria transmission was successfully imple-
mented as the first in the Southeast Asian context. More-
over, it proved to be a reliable, fast and useful method for 
simultaneous detection of Abs against Plasmodium Ags 
of three different Plasmodium parasites, which has never 
been done before. The assay was used to screen almost 
2000 field blood spot samples in duplicate and proved to 
be very time efficient and informative. It was also possible 
to estimate differences in the force of malaria infection, 
by looking at the differences in SCR over time between 
the different Ags. For a better estimation of changes in 
the force of infection on long-term as well as short-term 
in areas with low malaria endemicity, more informa-
tion on the longevity of the Ab responses is needed. The 
simultaneous detection of several Ags of different para-
sites offers an opportunity to look for a potential sero-
logical marker of very recent malaria transmission, which 
is the next step of this research. This will prove to be key 
knowledge for malaria elimination.
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